INBX logo

INBX
Inhibrx Inc

722
Mkt Cap
$1.61B
Volume
161,420.00
52W High
$155.29
52W Low
$12.25
PE Ratio
-13.11
INBX Fundamentals
Price
$109.99
Prev Close
$110.01
Open
$107.60
50D MA
$92.35
Beta
1.20
Avg. Volume
491,232.64
EPS (Annual)
-$9.04
P/B
-76.39
Rev/Employee
$11,818.18
$1,206.27
Loading...
Loading...
News
all
press releases
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Reports First Quarter 2026 Financial Results Inhibrx Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study...
Yahoo! Finance: News·7d ago
News Placeholder
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.read more...
Benzinga·10d ago
News Placeholder
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy Inhibrx Reports Interim Phase 2 Data for...
PR Newswire·10d ago
News Placeholder
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon...
PR Newswire·13d ago
News Placeholder
Credit Industriel ET Commercial Sells 20,302 Shares of Inhibrx Biosciences, Inc. $INBX
Credit Industriel ET Commercial decreased its position in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) by 70.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,656 shares of...
MarketBeat·15d ago
News Placeholder
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives Average Rating of "Hold" from Brokerages
Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) has received an average recommendation of 'Hold' from the six brokerages that are currently covering the firm, MarketBeat.com reports. One...
MarketBeat·16d ago
News Placeholder
Inhibrx Biosciences (NASDAQ:INBX) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised shares of Inhibrx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·20d ago
News Placeholder
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer
Inhibrx Biosciences (NASDAQ:INBX) shared a clinical update on ozekibart in advanced colorectal cancer, highlighting Phase I/II data evaluating ozekibart in combination with FOLFIRI in a heavily...
MarketBeat·26d ago
News Placeholder
Inhibrx Biosciences (NASDAQ:INBX) Upgraded at Lifesci Capital
Lifesci Capital raised shares of Inhibrx Biosciences to a "strong-buy" rating in a research report on Friday...
MarketBeat·26d ago
<
1
2
...
>

Latest INBX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.